Membrane receptors for peptides in experimental and human pancreatic cancers

M. Fekete, A. Zalatnai, A. M. Comaru-Schally, Andrew V Schally

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Membrane receptors for [D-Trp6]-luteinizing hormone-releasing hormone ([D-Trp6]-LH-RH), somatostatin (SS-14), and epidermal growth factor (EGF) were investigated in experimental N-nitrosobis-(2-oxopropyl)-amine (BOP)-induced pancreatic cancers of hamsters and in specimens of normal human pancreas and human pancreatic cancer obtained from autopsies. Membrane receptors for [D-Trp6]-LH-RH were absent in the pancreas of normal hamsters, but appeared after the carcinoma was induced with BOP. Binding capacity of SS-14 receptors was lower in membranes of BOP-induced pancreatic cancers than in the normal pancreas. In the BOP-induced pancreatic cancers, the receptors were also characterized following in vivo treatment of hamsters with microcapsules of the agonist [D-Trp6]-LH-RH, somatostatin analog RC-160, and the combination of both peptides, which resulted in significant tumor inhibition. Therapy with [D-Trp6]-LH-RH and RC-160, alone or in combination, decreased the binding capacity of receptors for [D-Trp6]-LH-RH, but increased B(max) for SS-14. There were no significant changes in characteristics of the EGF receptor following these therapies. Membranes from human pancreatic cancers showed binding sites for [D-Trp6]-LH-RH, but no binding was detected in normal human pancreas. The presence of receptors for LH-RH in pancreatic tumors of hamster and humans raises the intriguing possibility that LH-RH could be involved in complex interactions that contribute to the appearance of pancreatic cancer. The binding capacity of receptors for SS-14 in human pancreatic cancer membranes was lower, while B(max) for EGF was higher, as compared to normal pancreas. Observed changes in receptors and tumor suppression suggest that the agonist ]D-Trp6]-LH-RH and somatostatin analogs might exert some direct inhibitory effects on experimental pancreatic cancer of hamsters. It is possible that LH-RH agonists and somatostatin analogs could also be used for treatment of human pancreatic cancer. The presence of membrane receptors for [D-Trp6]-LH-RH, SS-14, and EGF in specimens of human pancreatic cancer also implies that this malignancy might be responsive to hormonal manipulations.

Original languageEnglish
Pages (from-to)521-528
Number of pages8
JournalPancreas
Volume4
Issue number5
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Peptide Receptors
Pancreatic Neoplasms
Gonadotropin-Releasing Hormone
Membranes
Cricetinae
Pancreas
Somatostatin
Epidermal Growth Factor
nitrosobis(2-oxopropyl)amine
Neoplasms
Epidermal Growth Factor Receptor
Capsules
Autopsy
Binding Sites

ASJC Scopus subject areas

  • Endocrinology
  • Gastroenterology

Cite this

Fekete, M., Zalatnai, A., Comaru-Schally, A. M., & Schally, A. V. (1989). Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas, 4(5), 521-528.

Membrane receptors for peptides in experimental and human pancreatic cancers. / Fekete, M.; Zalatnai, A.; Comaru-Schally, A. M.; Schally, Andrew V.

In: Pancreas, Vol. 4, No. 5, 01.01.1989, p. 521-528.

Research output: Contribution to journalArticle

Fekete, M, Zalatnai, A, Comaru-Schally, AM & Schally, AV 1989, 'Membrane receptors for peptides in experimental and human pancreatic cancers', Pancreas, vol. 4, no. 5, pp. 521-528.
Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV. Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas. 1989 Jan 1;4(5):521-528.
Fekete, M. ; Zalatnai, A. ; Comaru-Schally, A. M. ; Schally, Andrew V. / Membrane receptors for peptides in experimental and human pancreatic cancers. In: Pancreas. 1989 ; Vol. 4, No. 5. pp. 521-528.
@article{bb9c22c4964841c299d5f6f96fd28209,
title = "Membrane receptors for peptides in experimental and human pancreatic cancers",
abstract = "Membrane receptors for [D-Trp6]-luteinizing hormone-releasing hormone ([D-Trp6]-LH-RH), somatostatin (SS-14), and epidermal growth factor (EGF) were investigated in experimental N-nitrosobis-(2-oxopropyl)-amine (BOP)-induced pancreatic cancers of hamsters and in specimens of normal human pancreas and human pancreatic cancer obtained from autopsies. Membrane receptors for [D-Trp6]-LH-RH were absent in the pancreas of normal hamsters, but appeared after the carcinoma was induced with BOP. Binding capacity of SS-14 receptors was lower in membranes of BOP-induced pancreatic cancers than in the normal pancreas. In the BOP-induced pancreatic cancers, the receptors were also characterized following in vivo treatment of hamsters with microcapsules of the agonist [D-Trp6]-LH-RH, somatostatin analog RC-160, and the combination of both peptides, which resulted in significant tumor inhibition. Therapy with [D-Trp6]-LH-RH and RC-160, alone or in combination, decreased the binding capacity of receptors for [D-Trp6]-LH-RH, but increased B(max) for SS-14. There were no significant changes in characteristics of the EGF receptor following these therapies. Membranes from human pancreatic cancers showed binding sites for [D-Trp6]-LH-RH, but no binding was detected in normal human pancreas. The presence of receptors for LH-RH in pancreatic tumors of hamster and humans raises the intriguing possibility that LH-RH could be involved in complex interactions that contribute to the appearance of pancreatic cancer. The binding capacity of receptors for SS-14 in human pancreatic cancer membranes was lower, while B(max) for EGF was higher, as compared to normal pancreas. Observed changes in receptors and tumor suppression suggest that the agonist ]D-Trp6]-LH-RH and somatostatin analogs might exert some direct inhibitory effects on experimental pancreatic cancer of hamsters. It is possible that LH-RH agonists and somatostatin analogs could also be used for treatment of human pancreatic cancer. The presence of membrane receptors for [D-Trp6]-LH-RH, SS-14, and EGF in specimens of human pancreatic cancer also implies that this malignancy might be responsive to hormonal manipulations.",
author = "M. Fekete and A. Zalatnai and Comaru-Schally, {A. M.} and Schally, {Andrew V}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "4",
pages = "521--528",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Membrane receptors for peptides in experimental and human pancreatic cancers

AU - Fekete, M.

AU - Zalatnai, A.

AU - Comaru-Schally, A. M.

AU - Schally, Andrew V

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Membrane receptors for [D-Trp6]-luteinizing hormone-releasing hormone ([D-Trp6]-LH-RH), somatostatin (SS-14), and epidermal growth factor (EGF) were investigated in experimental N-nitrosobis-(2-oxopropyl)-amine (BOP)-induced pancreatic cancers of hamsters and in specimens of normal human pancreas and human pancreatic cancer obtained from autopsies. Membrane receptors for [D-Trp6]-LH-RH were absent in the pancreas of normal hamsters, but appeared after the carcinoma was induced with BOP. Binding capacity of SS-14 receptors was lower in membranes of BOP-induced pancreatic cancers than in the normal pancreas. In the BOP-induced pancreatic cancers, the receptors were also characterized following in vivo treatment of hamsters with microcapsules of the agonist [D-Trp6]-LH-RH, somatostatin analog RC-160, and the combination of both peptides, which resulted in significant tumor inhibition. Therapy with [D-Trp6]-LH-RH and RC-160, alone or in combination, decreased the binding capacity of receptors for [D-Trp6]-LH-RH, but increased B(max) for SS-14. There were no significant changes in characteristics of the EGF receptor following these therapies. Membranes from human pancreatic cancers showed binding sites for [D-Trp6]-LH-RH, but no binding was detected in normal human pancreas. The presence of receptors for LH-RH in pancreatic tumors of hamster and humans raises the intriguing possibility that LH-RH could be involved in complex interactions that contribute to the appearance of pancreatic cancer. The binding capacity of receptors for SS-14 in human pancreatic cancer membranes was lower, while B(max) for EGF was higher, as compared to normal pancreas. Observed changes in receptors and tumor suppression suggest that the agonist ]D-Trp6]-LH-RH and somatostatin analogs might exert some direct inhibitory effects on experimental pancreatic cancer of hamsters. It is possible that LH-RH agonists and somatostatin analogs could also be used for treatment of human pancreatic cancer. The presence of membrane receptors for [D-Trp6]-LH-RH, SS-14, and EGF in specimens of human pancreatic cancer also implies that this malignancy might be responsive to hormonal manipulations.

AB - Membrane receptors for [D-Trp6]-luteinizing hormone-releasing hormone ([D-Trp6]-LH-RH), somatostatin (SS-14), and epidermal growth factor (EGF) were investigated in experimental N-nitrosobis-(2-oxopropyl)-amine (BOP)-induced pancreatic cancers of hamsters and in specimens of normal human pancreas and human pancreatic cancer obtained from autopsies. Membrane receptors for [D-Trp6]-LH-RH were absent in the pancreas of normal hamsters, but appeared after the carcinoma was induced with BOP. Binding capacity of SS-14 receptors was lower in membranes of BOP-induced pancreatic cancers than in the normal pancreas. In the BOP-induced pancreatic cancers, the receptors were also characterized following in vivo treatment of hamsters with microcapsules of the agonist [D-Trp6]-LH-RH, somatostatin analog RC-160, and the combination of both peptides, which resulted in significant tumor inhibition. Therapy with [D-Trp6]-LH-RH and RC-160, alone or in combination, decreased the binding capacity of receptors for [D-Trp6]-LH-RH, but increased B(max) for SS-14. There were no significant changes in characteristics of the EGF receptor following these therapies. Membranes from human pancreatic cancers showed binding sites for [D-Trp6]-LH-RH, but no binding was detected in normal human pancreas. The presence of receptors for LH-RH in pancreatic tumors of hamster and humans raises the intriguing possibility that LH-RH could be involved in complex interactions that contribute to the appearance of pancreatic cancer. The binding capacity of receptors for SS-14 in human pancreatic cancer membranes was lower, while B(max) for EGF was higher, as compared to normal pancreas. Observed changes in receptors and tumor suppression suggest that the agonist ]D-Trp6]-LH-RH and somatostatin analogs might exert some direct inhibitory effects on experimental pancreatic cancer of hamsters. It is possible that LH-RH agonists and somatostatin analogs could also be used for treatment of human pancreatic cancer. The presence of membrane receptors for [D-Trp6]-LH-RH, SS-14, and EGF in specimens of human pancreatic cancer also implies that this malignancy might be responsive to hormonal manipulations.

UR - http://www.scopus.com/inward/record.url?scp=0024437217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024437217&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 521

EP - 528

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 5

ER -